Education
About Us
Working with TipRanks
Follow Us
Argent Biopharma (AU:RGT)
ASX:RGT
RGT Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.07 - AU$0.57
Previous CloseN/A
Volume362.25K
Average Volume (3M)166.90K
Market Cap
$8.68M
Enterprise ValueAU$13.11M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.71
Next Earnings
Feb 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding75,516,490
10 Day Avg. Volume110,537
30 Day Avg. Volume166,898
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Argent Biopharma News
RGT FAQ
What was Argent Biopharma’s price range in the past 12 months?
Argent Biopharma lowest share price was AU$0.07 and its highest was AU$0.57 in the past 12 months.
What is Argent Biopharma’s market cap?
Argent Biopharma’s market cap is $8.68M.
When is Argent Biopharma’s upcoming earnings report date?
Argent Biopharma’s upcoming earnings report date is Feb 27, 2026 which is in 170 days.
How were Argent Biopharma’s earnings last quarter?
Argent Biopharma released its earnings results on Aug 28, 2025. The company reported -AU$0.079 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.079.
Is Argent Biopharma overvalued?
According to Wall Street analysts Argent Biopharma’s price is currently Overvalued.
Does Argent Biopharma pay dividends?
Argent Biopharma does not currently pay dividends.
What is Argent Biopharma’s EPS estimate?
Argent Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argent Biopharma have?
Argent Biopharma has 75,516,490 shares outstanding.
What happened to Argent Biopharma’s price movement after its last earnings report?
Argent Biopharma reported an EPS of -AU$0.079 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.897%.
Which hedge fund is a major shareholder of Argent Biopharma?
Currently, no hedge funds are holding shares in AU:RGT
Argent Biopharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
AU:RGT Sentiment 100%
Sector Average 71%
Sector Average 71%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-77.55%
Trailing 12-Months
Company Description
Argent Biopharma
MGC Pharmaceuticals Ltd is a European-based specialist Medical Cannabis company, in Phytocannabinoid-based medicine within the biopharmaceutical industry. The company's principal business goal is to produces and supply quality Cannabinoid based pharmaceutical products for the emergent medical markets in Europe, North America and Australasia.
Technical Analysis
Genetic Technologies
―
Zelira Therapeutics
―
EVE Health Group Limited
―
Adherium Ltd.
―
Bio-Gene Technology Ltd.
―
Options Prices
Currently, No data available
---